FLASCO
- FLASCO Proudly Announces the Release of a New White Paper Providing Practical Guidance on Expanding Access to Innovative Cancer Therapies March 24, 2025FLASCO is pleased to share a new white paper exploring the transformative potential of bispecific antibodies (BsAbs) in lymphoma treatment. Developed with support from Genentech, the paper offers actionable recommendations for wider adoption across Florida. With demonstrated success in clinical trials, BsAbs represent a significant advancement in cancer care. The report highlights the importance of...
- FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 19, 2025On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
- Social Determinants of Health in Florida March 5, 2025
- FDA Issues FY24 Drug Safety Priorities Report February 26, 2025CDER’s latest Drug Safety Priorities Fiscal Year 2024 report highlights the extensive work of its multidisciplinary teams, showcasing significant safety-related milestones and achievements. These efforts underscore CDER’s ongoing commitment to promote and protect public health by addressing potential medication risks and enhancing safety measures. The report highlights continuing initiatives to combat the overdose crisis, including...
- FLASCO to Host Two Premier Oncology Training Programs at Moffitt Cancer Center in March 2025 February 25, 2025Press Release by Kellie Jordan RIVERVIEW, FL – February 25, 2026 – The Florida Society of Clinical Oncology (FLASCO) is pleased to announce the return of two premier oncology training programs: Great Strides Together on March 8, 2025, and Rapid Integrations on March 9, 2025. These back-to-back educational initiatives will take place at Moffitt Cancer Center in Tampa, FL,...
- FLASCO OncoFeature – Nuturing the Next Generation of Oncologists February 21, 2025Press Release by Kellie Jordan RIVERVIEW, FL – February 21, 2025 – Next month, the Florida Society of Clinical Oncology (FLASCO) is holding the annual 2025 FLASCO Fellows & Residents Training Program, a one-day educational event designed to empower and support the next generation of oncology professionals. The program will take place on March 22,...
- FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor February 15, 2025On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
- FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma February 12, 2025On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade...
- FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection February 11, 2025On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
- Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial February 11, 2025This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the bile ducts in the liver) that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are...